HONEYWELL TECHNOLOGY TO POWER DEVPRO BIOPHARMA’S NEXT-GENERATION LOW-EMISSION RESPIRATORY INHALER

Honeywell Solstice® Air can cut metered dose inhaler greenhouse gas emissions of up to 99.9% versus current propellants¹

CHARLOTTE, N.C., October, 2024 – Honeywell (NASDAQ: HON) today announced a long-term supply agreement with DevPro Biopharma to develop a respiratory inhaler that enhances the well-being of patients while reducing carbon emissions associated with the use of traditional inhalers. This new relationship with DevPro Biopharma also supports Honeywell’s alignment of its portfolio to several powerful megatrends, including the energy transition.

By using Honeywell Solstice^® Air HFO-1234ze technology, a low global warming potential (GWP) propellant, DevPro Biopharma’s new albuterol inhaler will reduce carbon emissions by 99.9% compared to conventional inhalers without compromising inhaler efficacy, enabling patients to manage their respiratory conditions while also contributing to reduced carbon emissions.

Albuterol inhalers are life-saving devices used by those with asthma and Chronic Obstructive Pulmonary Disease (COPD). Globally, as many as 384 million people suffer from COPD – the third leading cause of death according to the World Health Organization¹– and 262 million suffer from asthma.²

"There's a pressing need to develop an albuterol inhaler that reduces environmental impact while maintaining its efficacy in treating respiratory conditions,” said DevPro CEO and Co-Founder Colin Reisner. “By transitioning to low-carbon propellant alternatives through our supplier relationship with Honeywell, we're excited to accelerate development on this groundbreaking product."

Solstice Air is a breakthrough for pressurized metered dose inhalers (pMDIs), providing a low-GWP alternative to other commonly used hydrofluorocarbons, which are a critical part of propelling medication directly to a patient’s lungs.

“Solstice Air will play a critical role in helping to ensure DevPro Biopharma’s life-saving devices are both effective and aligned with environmental goals,” said Jeff Dormo, president of Honeywell’s Sustainability and Decarbonization business. “By continuing to research and develop lower carbon emission technology, Honeywell is committed to driving innovation that not only enhances health outcomes but also protects our planet for future generations.”

Clinical trials for DevPro Biopharma’s new inhaler are expected to start in 2025, with consumer availability projected for early 2027.

For more information on Honeywell Solstice Air, its applications and impact, visit https://sustainability.honeywell.com/us/en.

References:

¹Studies conducted by UNEP and American Lung Association https://www.unep.org/news-and-stories/story/how-do-greenhouse-gases-actually-warm-planet https://www.lung.org/getmedia/cfe2481d-1478-4cea-8a77-1ac3eb112e71/what-you-should-know-ways.pdf

²World Health Organization. Chronic obstructive pulmonary disease (COPD) key facts [Online]. Available at: https://www.who.int/news-room/fact-sheets/detail/chronic-obstructive-pulmonary-disease-(copd)        

³The Global Asthma Network. The Global Asthma Report 2022. [Online]. Available at: https://www.globalasthmanetwork.org/; World Health Organization. The top 10 causes of death. [Online].